Pharmacoeconomic aspects of biosimilars
The tendency towards replacement of reference preparation for biosimilars can be observed around the world. Registrational studies, concerning biosimilars suggest the comparison of pharmacokinetics and pharmacodynamics of drugs, as well as their clinical efficacy, tolerability and immunogenicity in...
Main Authors: | A A Tryakin, A V Rudakova, S N Fogt, A S Vaganov, D G Tolkacheva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IP Habib O.N.
2017-01-01
|
Series: | Современная онкология |
Subjects: | |
Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/27119/pdf |
Similar Items
-
The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study)
by: M. A. Korolev, et al.
Published: (2021-01-01) -
TROIKA‐1: A double‐blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU‐Herceptin® and US‐Herceptin® in healthy male subjects
by: Martin Demarchi, et al.
Published: (2021-08-01) -
Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa
by: Almaaytah A
Published: (2020-09-01) -
Major Advances in the Treatment of Cancer What does a Non-Oncologist need to know?
by: Ikram A Burney, et al.
Published: (2008-07-01) -
Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study
by: M. Yu. Fedyanin, et al.
Published: (2021-06-01)